2/24/2020 7:08:38 AM
Lipocine Announces Results Of Post Action Meeting For TLANDO NDA; Says Regulatory Path Forward For TLANDO Resubmission
11/11/2019 6:31:32 AM
Lipocine Receives Complete Response Letter For TLANDO From FDA
8/7/2019 8:08:40 AM
Lipocine Q2 Net Loss $3.4 Mln Or $0.14/shr Vs. Net Loss Of $3.3 Mln Or $0.15/shr Prior Year
7/23/2019 8:04:23 AM
Lipocine Gets FDA Clearance For Clinical Testing Its NASH Candidate, LPCN 1144, In Expanded Target Population
5/8/2019 8:04:41 AM
Lipocine Q1 Net Loss $3.2 Mln Or $0.14/shr Vs Net Loss Of $2.7 Mln Or $0.13/shr Prior Year
3/14/2019 8:07:50 AM
Lipocine Announces Presentation Highlighting Therapeutic Potential Of LPCN 1144 In NAFLD And NASH Selected For ENDO 2019
3/12/2019 8:06:39 AM
Lipocine Announces Top-line Results From 16-week Liver Fat Imaging Study With LPCN 1144
1/24/2019 8:08:42 AM
Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects
1/14/2019 8:17:06 AM
Lipocine Says USPTO Grants Priority Motion To Company And Enters Judgment Against Clarus
12/31/2018 8:01:02 AM
Lipocine Announces Completion Of Phlebotomy Study
12/21/2018 8:02:33 AM
Lipocine Announces LPCN 1144 Clinical Trial Results Selected For Presentation
12/21/2018 8:01:58 AM
Lipocine Announces LPCN 1144 Clinical Trial Results Selected For Presentation At 2019 NASH-TAG Conference